Evolution Wealth Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Evolution Wealth Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-162	Closed	-$3K	–	145
2021 Q3	$3K	Sell	162 -200	-55%	-$3.85K	﹤0.01%	588
2021 Q2	$9K	Sell	362 -216	-37%	-$4.88K	﹤0.01%	418
2021 Q1	$15K	Buy	578 +75	+15%	+$3.3K	﹤0.01%	337
2020 Q4	$27K	Sell	503 -152	-23%	-$7.55K	0.01%	228
2020 Q3	$27K	Buy	655 +250	+62%	+$10.8K	0.01%	239
2020 Q2	$20K	Buy	+405	New	+$19.4K	0.01%	202

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Evolution Wealth Advisors's ACAD Position: Q4 2021 in Review

Evolution Wealth Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q4 2021, closing a stake of 162 shares — an estimated $3K sold.

Evolution Wealth Advisors first reported a position in ACAD in Q2 2020 and held it in 6 quarters. The position peaked at $27K in Q4 2020. 247 funds tracked by Wall St. Rank hold ACAD as of Q4 2021.

Evolution Wealth Advisors reported no remaining Acadia Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Evolution Wealth Advisors sold 162 Acadia Pharmaceuticals shares in Q4 2021, an estimated $3K.
Evolution Wealth Advisors first reported a position in Acadia Pharmaceuticals in Q2 2020 and held it in 6 quarters.
Evolution Wealth Advisors's Acadia Pharmaceuticals position peaked at $27K in Q4 2020.
247 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2021.

Based on Evolution Wealth Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.